【摘要】 目的：分析经导管肝动脉化疗栓塞术（TACE）联合系统抗肿瘤治疗在原发性肝癌（PHC）中的临床应用效果。方法：研究时间为2023年2月—2024年2月，择取潍坊市中医院收治的76例PHC患者，通过随机抽签法分为观察组、对照组，各38例。对照组患者行系统抗肿瘤治疗，观察组患者行TACE与系统抗肿瘤治疗。系统抗肿瘤治疗3个月后，比较两组临床疗效、肝功能指标、血清因子指标[血管内皮生长因子（VEGF）、基质金属蛋白酶-9(MMP-9)、甲胎蛋白（AFP）、糖类抗原19-9(CA19-9)]，并比较两组的不良反应发生率。结果：观察组疾病控制率、客观缓解率高于对照组（P<0.05）；治疗后，观察组AST、ALT、TBIL水平低于对照组，白蛋白（ALB）水平高于对照组（P<0.05）；治疗后，观察组血清因子水平低于对照组（P<0.05）；两组不良反应发生率比较，差异无统计学意义（P>0.05）。结论：TACE联合系统抗肿瘤治疗在PHC中的应用效果显著，可改善患者肝功能，降低多项血清因子水平，且不增加不良反应发生风险。更多还原

【Abstract】 Objective: To analyze the clinical application effect of transcatheter arterial chemoembolization(TACE) combined with systemic anti-tumor therapy in primary hepatic carcinoma(PHC). Method: The research period was from February 2023 to February 2024. A total of 76 patients with PHC admitted to Weifang Hospital of Traditional Chinese Medicine were selected and divided into the observation group and the control group by randomly lottery method, with 38 cases in each group. Patients in the control group received systemic anti-tumor therapy, and those in the observation group received TACE combined with systemic anti-tumor therapy. Three months after the systemic anti-tumor therapy, the clinical efficacy, liver function indicators, serum factor indicators [vascular endothelial growth factor(VEGF), matrix metalloproteinase-9(MMP-9), alpha-fetoprotein(AFP) and carbohydrate antigen 19-9(CA19-9)] were compared between the two groups, and the incidence of adverse reactions in the two groups was compared. Result: The disease control rate and objective response rate of the observation group were higher than those of the control group(P<0.05). After treatment, the levels of AST, ALT and TBIL in the observation group were lower than those in the control group, and the albumin(ALB) level was higher than that in the control group(P<0.05). After treatment, the serum factors levels in the observation group were lower than those in the control group(P<0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05). Conclusion: The application effect of TACE and systemic anti-tumor therapy in PHC is remarkable. It can improve liver function in patients, reduce the levels of multiple serum factors, and does not increase the risk of adverse reactions.更多还原